UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for hepatocellular carcinoma (liver cancer) in the United Kingdom. Explore treatment pathways including immunotherapy, targeted therapy, and locoregional treatments.
Primary liver cancer (hepatocellular carcinoma, HCC) affects ~6,100 people per year in the UK. It often develops in people with chronic liver disease, particularly cirrhosis from hepatitis B, hepatitis C, alcohol, or fatty liver disease (NAFLD). Many cases are diagnosed late. Treatment depends on liver function, tumour extent, and the patient's overall health.
Early stage: surgery (resection) or liver transplant. Intermediate: locoregional therapies (TACE - transarterial chemoembolisation, ablation). Advanced: immunotherapy combination atezolizumab + bevacizumab is now first-line, significantly improving survival. Alternatives include TKIs (sorafenib, lenvatinib). Second-line options: regorafenib, cabozantinib, ramucirumab (for high AFP).
Active UK trials include: new immunotherapy combinations (anti-PD1 + anti-CTLA-4 + anti-VEGF), bispecific antibodies, combination locoregional + systemic therapy, Y90 radioembolisation, and approaches targeting the tumour microenvironment. NHS liver centres collaborate through the National Cancer Research Institute.
22 recruiting trials — 1 early-stage, 2 locally advanced, 5 recurrent or metastatic, 14 stage not specified
Free AI-powered matching - no signup required
Search hepatocellular carcinoma Trials →